CLINICAL_TRIALS
trial_result
· 2022-02-10
Clinical Trial Update: Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy [Phase 2]
Summary
Phase 2 trial of AVB-S6-500 in IgA nephropathy was terminated; results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Aravive, Inc. | Conditions: IgA Nephropathy | Phase 2 | Status: TERMINATED | Results posted: 2022-02-10